Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care

Introduction Several cardiovascular outcome trials have been conducted to assess the cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on cardiorenal outcomes in patients with type-2 diabetes (T2D). However, the strict requirements of randomised controlled tr...

Full description

Bibliographic Details

Published in:	BMJ Open
Main Authors:	François Schiele, Mikael Mazighi, Nicolas Danchin, Igor Sibon, Gilles Lemesle, Kamel Mohammedi, Laurent Fauchier, Bruno Detournay, Alexandre Caron, Corinne Emery, Camille Nevoret, Lucile Vigié, Christine Massien
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Online Access:	https://bmjopen.bmj.com/content/15/1/e087790.full